Keytruda pembrolizumab: Additional Phase I/II data

Data from 74 chemotherapy-naive patients with advanced EGFR- and anaplastic lymphoma kinase (ALK)-negative NSCLC in cohorts A-C of the open-label, international Phase I/II KEYNOTE-021 trial showed that 2 or 10 mg/kg IV

Read the full 323 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE